Literature DB >> 29470103

An Approach to Children with Pulmonary Edema at High Altitude.

Deborah R Liptzin1, Steven H Abman1, Ann Giesenhagen2, D Dunbar Ivy2.   

Abstract

Liptzin, Deborah R., Steven H. Abman, Ann Giesenhagen, and D. Dunbar Ivy. An approach to children with pulmonary edema at high altitude. High Alt Med Biol. 19:91-98, 2018.
INTRODUCTION: Diagnosis of high-altitude illness can be more challenging in children, especially those who are preverbal. Families often travel to high elevations for family vacations, either for skiing, hiking, and/or camping. They may present to their primary care providers looking for anticipatory guidance before travel or may follow-up after developing high-altitude illness. High-altitude pulmonary edema (HAPE) can be fatal. OBSERVATIONS: There is no indication for HAPE prophylaxis in altitude naive children. Children may develop HAPE either when traveling from low altitude to high altitude for vacation (classic HAPE), when returning to high-altitude homes after travel to low altitude (reentry HAPE), or even with a respiratory illness at high altitude without any change in elevation (high-altitude resident pulmonary edema or HARPE). Children may be more susceptible to HAPE because of increased vascular reactivity, immature control of breathing, and increased frequency of respiratory illnesses. Children with HAPE warrant evaluation for underlying cardiopulmonary abnormalities, including structural heart disease and pulmonary hypertension. Treatment of HAPE includes supplemental oxygen and descent, but underlying cardiopulmonary disease may also help guide treatment and prevention. CONCLUSIONS AND RELEVANCE: Evaluation for structural heart disease and pulmonary hypertension should be considered in children with HAPE. Future studies should be done to elucidate the optimal strategies for prevention and treatment of HAPE and to better understand the development of HAPE in children.

Entities:  

Keywords:  altitude; cardiac disease; pediatrics; pulmonary hypertension

Mesh:

Year:  2018        PMID: 29470103      PMCID: PMC5905943          DOI: 10.1089/ham.2017.0096

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  51 in total

1.  Lack of evidence for association of high altitude pulmonary edema and polymorphisms of the NO pathway.

Authors:  Johanna Weiss; Walter Emil Haefeli; Christiane Gasse; Michael Marcus Hoffmann; Jörn Weyman; Simon Gibbs; Ulrich Mansmann; Peter Bärtsch
Journal:  High Alt Med Biol       Date:  2003       Impact factor: 1.981

2.  Pathological features of the lung in fatal high altitude pulmonary edema occurring at moderate altitude in Japan.

Authors:  Y Droma; M Hanaoka; J Hotta; A Naramoto; T Koizumi; K Fujimoto; T Honda; T Kobayashi; K Kubo
Journal:  High Alt Med Biol       Date:  2001       Impact factor: 1.981

3.  Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial.

Authors:  Marco Maggiorini; Hans-Peter Brunner-La Rocca; Simon Peth; Manuel Fischler; Thomas Böhm; Alain Bernheim; Stefanie Kiencke; Konrad E Bloch; Christoph Dehnert; Robert Naeije; Thomas Lehmann; Peter Bärtsch; Heimo Mairbäurl
Journal:  Ann Intern Med       Date:  2006-10-03       Impact factor: 25.391

4.  High altitude pulmonary edema. Epidemiologic observations in Peru.

Authors:  H N Hultgren; E A Marticorena
Journal:  Chest       Date:  1978-10       Impact factor: 9.410

5.  High-altitude pulmonary edema in persons without the right pulmonary artery.

Authors:  P H Hackett; C E Creagh; R F Grover; B Honigman; C S Houston; J T Reeves; A M Sophocles; M Van Hardenbroek
Journal:  N Engl J Med       Date:  1980-05-08       Impact factor: 91.245

6.  High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude.

Authors:  Bibhuti B Das; Robert R Wolfe; Kak-Chen Chan; Gary L Larsen; John T Reeves; Dunbar Ivy
Journal:  Arch Pediatr Adolesc Med       Date:  2004-12

7.  Increased lung vasoreactivity in children from Leadville, Colorado, after recovery from high-altitude pulmonary edema.

Authors:  J W Fasules; J W Wiggins; R R Wolfe
Journal:  Circulation       Date:  1985-11       Impact factor: 29.690

8.  Use of the Gamow Bag by EMT-basic park rangers for treatment of high-altitude pulmonary edema and high-altitude cerebral edema.

Authors:  Kimberly Freeman; Marc Shalit; Geoffrey Stroh
Journal:  Wilderness Environ Med       Date:  2004       Impact factor: 1.518

Review 9.  Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness.

Authors:  Andrew M Luks; Erik R Swenson
Journal:  Chest       Date:  2008-03       Impact factor: 9.410

10.  Polymorphisms of the tissue inhibitor of metalloproteinase 3 gene are associated with resistance to high-altitude pulmonary edema (HAPE) in a Japanese population: a case control study using polymorphic microsatellite markers.

Authors:  Nobumitsu Kobayashi; Masayuki Hanaoka; Yunden Droma; Michiko Ito; Yoshihiko Katsuyama; Keishi Kubo; Masao Ota
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

View more
  2 in total

1.  High Altitude Pulmonary Edema in Children: A Single Referral Center Evaluation.

Authors:  Ann M Giesenhagen; D Dunbar Ivy; John T Brinton; Maxene R Meier; Jason P Weinman; Deborah R Liptzin
Journal:  J Pediatr       Date:  2019-04-17       Impact factor: 4.406

2.  Expression of Aquaporin-1 and Aquaporin-5 in a Rat Model of High-Altitude Pulmonary Edema and the Effect of Hyperbaric Oxygen Exposure.

Authors:  Jiewen Tan; Chunjin Gao; Cong Wang; Linlin Ma; Xiaomin Hou; Xuehua Liu; Zhuo Li
Journal:  Dose Response       Date:  2020-10-30       Impact factor: 2.658

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.